• Product NameLDK378(Ceritinib)
• Brief DescriptionInhibitors
• Purification99.50%
• Biological ActivityCeritinib is an orally available inhibitor of the receptor tyrosine kinase activity of anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, ceritinib binds to and inhibits wild-type ALK kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to both the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a variety of tumor cell types.
• Target NameALK inhibitor; FLT inhibitor; IGF-1R inhibitor; Serine Protease inhibitor
• CAS No. 1032900-25-6
• Calculated MW 558.14
• Formulation C28H36ClN5O3S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
  Pathways:Angiogenesis; Proteases/Proteasome; Tyrosine Kinase/Adaptors
  Receptor:ALK; FLT3; IGF-1R; Insulin Receptor; STK22D
  Boling pt:
  Melting pt:
  Solubility:Ethanol: 3 mg/mL (5.37 mM); DMSO: 20 mg/mL warmed (35.83 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Marsilje TH, et al. J Med Chem. 2013, Jun 6.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting